Dr. Clay Siegall vs The Fight Against Cancer

When it comes to dealing with and treating cancer, nothing is left to chance. This deadly disease has destroyed the lives of millions of people worldwide. On the other hand, cancer research has done its best treating the disease, but with only so little luck. As of today, the fight against cancer is much more promising thanks to Seattle Genetics. Seattle Genetics, located in Bothell, Washington, is the largest oncology biotech company in the Puget Sound region. This company specializes in developing and commercializing antibody-based therapies. These therapies come in the form of antibody-drug conjugates. ADCs are producing much better results than medications of the past thanks to its powerful delivery.

President and CEO Clay Siegall is running the company at full throttle. Siegall has decades of experience in the game, and he has become the face for the fight against cancer. Siegall has an extensive educational background that most people can only dream of. The guy is known as a doctor, a scientist, an author and a philanthropist. His dedication to his services is unmatched by his peers. The company focuses on rigorous research, and this rigorous research is paying off by saving lives. Siegall’s leadership is unmatched also as he has been able to get the company’s flagship drug ADCETRIS, approved for use. As of today, ADCETRIS is being used in up to 65 different countries worldwide. The drug is one of the most successful drugs for fighting cancer as it attacks cancerous cells with a cell killing blow. By obtaining multiple strategic licenses, the ADCs have earned upward of $350 million.

Dr. Siegall does a great job by keeping people informed with the latest news of the industry. He blogs on a regular basis, and he talks about a wide range of topics from within the industry. With his strong love of astronomy, he regularly speaks on the topic of science and the planets. With many more drugs in the pipeline of success, Seattle Genetics is looking to increase its grip via antibody-based therapies.